Patients with lupus had fivefold greater representation of Ruminococcus gnavus
WEDNESDAY, Feb. 20, 2019 (HealthDay News) — The microbiome of patients with systemic lupus erythematosus (SLE), particularly those with increased disease activity, has reduced taxonomic complexity, according to a study published online Feb. 19 in the Annals of the Rheumatic Diseases.
Doua Azzouz, Ph.D., from the New York University (NYU) School of Medicine in New York City, and colleagues obtained matched blood and fecal samples from 61 female patients with SLE. Fecal 16S rRNA analyses were performed, and sera were profiled for antibacterial and autoantibody responses. Findings were validated in two independent cohorts.
The researchers found that in patients with SLE, the microbiome showed decreased species richness diversity compared with controls; the most pronounced reductions in taxonomic complexity were seen for those with a high SLE disease activity index (SLEDAI). An overall fivefold greater representation of Ruminococcus gnavus (RG) of the Lachnospiraceae family was seen in patients with SLE; reciprocal contractions of a species with putative protective properties were also seen in individual communities. There was a correlation for gut RG abundance with serum antibodies to only one of eight RG strains tested. There was a direct correlation for anti-RG antibodies with SLEDAI score and antinative DNA levels, and there were inverse correlations with C3 and C4. Individuals with active nephritis had the highest levels of serum anti-RG strain-restricted antibodies in the discovery cohort; this finding was replicated in the validation cohorts.
“Our analyses provide the first evidence that lupus is associated with intestinal outgrowths of RG, an obligate anaerobic species,” the authors write.
NYU has filed intellectual property related to this study.
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis